Newland Pharmaceutical Co., Ltd. (Stock Abbreviation: Newland Pharma, Stock Code: 301277, Announcement Number: 2026-019)
Announcement Regarding Retirement of Senior Management and Appointment of Senior Management
The company and the board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement and that there are no false representations, misleading statements, or material omissions.
Newland Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held its Twelfth Meeting of the Sixth Board of Directors on April 23, 2026, which reviewed and approved the "Proposal on Appointing the Company's Deputy General Manager." The details are as follows:
I. Retirement of Senior Management
The Company's Board of Directors recently received a written resignation report from Ms. Wang Liying, Deputy General Manager. Ms. Wang Liying has applied to resign from her position as Deputy General Manager of the Company due to reaching the statutory retirement age. Ms. Wang Liying's original term was scheduled to end on April 23, 2027. Following her resignation from the aforementioned position, the Company will re-employ Ms. Wang Liying as an advisor to the Company.